Gemcitabine and docetaxel for metastatic soft tissue sarcoma - a single center experience.


BACKGROUND Prognosis and survival for patients with metastatic soft tissue sarcoma (STS) are dismal. Standard first-line systemic chemotherapy is anthracycline-based. Gemcitabine/docetaxel (GD) is a therapeutic option in the second-line setting. Here we present the data of our single center retrospective analysis, using GD in locally advanced or metastatic… (More)
DOI: 10.1159/000353564


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics